Utility of Lymphadenectomy in Prostate Cancer: Where do We Stand?

Bartosz Małkiewicz; Paweł Kiełb; Jakub Karwacki; Róża Czerwińska; Paulina Długosz; Artur Lemiński; Łukasz Nowak; Wojciech Krajewski; Tomasz Szydełko

doi:10.20944/preprints202203.0197.v1

A peer-reviewed article of this Preprint also exists.

Małkiewicz, B.; Kiełb, P.; Karwacki, J.; Czerwińska, R.; Długosz, P.; Lemiński, A.; Nowak, Ł.; Krajewski, W.; Szydełko, T. Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand? J. Clin. Med. 2022, 11, 2343. Małkiewicz, B.; Kiełb, P.; Karwacki, J.; Czerwińska, R.; Długosz, P.; Lemiński, A.; Nowak, Ł.; Krajewski, W.; Szydełko, T. Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand? J. Clin. Med. 2022, 11, 2343.

Abstract

The purpose of this review is to summarize current knowledge on lymph node dissection (LND) in prostate cancer (PCa) patients undergoing radical prostatectomy (RP). Despite a growing body of evidence, utility, therapeutic and prognostic value of such approach as well as optimal extent of LND, remain unsolved issues. Although LND is the most accurate staging procedure, the direct therapeutic effect is still not evident from the current literature which limits the possibility of establishing clear recommendations. This indicates the need for further robust and adequately designed high quality clinical trials.

Keywords

Subject

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Utility of Lymphadenectomy in Prostate Cancer: Where do We Stand?

Abstract

Keywords

Subject

Comments (0)